Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)
NCT ID: NCT00488917
Last Updated: 2009-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
167 participants
OBSERVATIONAL
2007-06-30
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Indicators of Inflammation and Coagulation in Sepsis
NCT01128283
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock
NCT02163473
Prevelance, Predictors and Outcome of Sepsis Associated Liver Injury (SALI)
NCT06758908
Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis
NCT01012115
Serum TNF-a in Comparison to Sequential Organ Failure Assessment (SOFA) Score Monitoring in Critically Ill Patients
NCT01708772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Septic complications in patients with liver failure may induce a disruption of liver microcirculation, which is regulated by several factors acting on endothelial and liver stellate cells. Furthermore, generation of reactive oxygen species results in an oxidative stress on lipids, proteins, and DNA. Lipid peroxidation may contribute to further hepatocellular injury and activation of systemic inflammation cascade. Both endothelial dysfunction and alterations in lipid metabolism may have a role in the prognosis of liver disease and its complications.
The purpose of this prospective observational study is to determine the role of new biomarkers in the diagnosis of sepsis in critically-ill patients with liver failure and to correlate the prognosis of these patients with parameters of endothelial function and lipid metabolism. In addition, the porto-systemic gradient of these parameters will be determined in patients planned for a transjugular intra-hepatic porto-systemic shunt (TIPSS).
An overall number of 120 patients will be enrolled. According to the mode of presentation, the planned number of patients in the different study groups will be as follow : 70 patients with chronic liver failure and acute on chronic liver failure; 20 patients with acute liver failure ; 30 patients post-liver transplantation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patient aged 18 years or above, and less than 85 ;
* Admission to the ICU for an expected period of \> 24 hours or elective admission for TIPSS placement ;
* Informed consent of the patient or nearest relative.
Exclusion Criteria
* Pregnancy, including HELLP syndrome ;
* Acquired immunodeficiency syndrome and antiretroviral therapy ;
* Refusal of the patient or nearest relative.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cliniques universitaires Saint-Luc, Université catholique de Louvain
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre-François Laterre, MD
Role: STUDY_DIRECTOR
Cliniques Universitaires St Luc, Université Catholique de Louvain
Yvan Fleury, MD
Role: PRINCIPAL_INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cliniques Universitaires St Luc, Université Catholique de Louvain
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B40320072194
Identifier Type: -
Identifier Source: secondary_id
SELLIFA-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.